A Pilot Study to Assess the Use of Methylone in the Treatment of PTSD IMPACT-1 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD]) - TT-TSND-201

Transcend Therapeutics Inc.0 个研究点目标入组 79 人开始时间: 2023年6月8日最近更新: 2024年7月22日

试验速览

暂无简介。

•Meets the DSM-5 criteria for current moderate to severe PTSD diagnosis, with a symptom duration of at least 6 months. (The PTSD diagnosis will be confirmed at Baseline by the central rater)., CAPS-5 score of ‚ =35 at Screening and =28 at Baseline., Failed at least one treatment for PTSD (either psychotherapy or pharmacological treatment)., Proficient in reading and writing in local language sufficient to complete questionnaires., Free from any other clinically significant illness or disease

•Primary diagnosis of any other DSM-5 disorder, Body mass index (BMI) <18 kg/m2 or ‚=40 kg/m2, Smokes an average of >10 cigarettes and/or e-cigarettes per day, Uncontrolled hypertension at Screening, Use of a psychedelic (e.g., LSD, psilocybin, DMT, mescaline), or entactogens such as MDMA, within 12 months of Screening., Use of an SSRI or other antidepressant within 8 weeks of screening, Current or previous history of clinically significant cardiovascular/cerebrovascular conditions

发起方

Transcend Therapeutics Inc.